Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Blood Advances|August 5, 2025
Safety and Efficacy of Daratumumab in Immune ThrombocytopeniaGalina Tsykunova, Pål Andre Holme, Hoa Thi Thyuet Tran, et al.
Frontiers in Immunology|February 1, 2024
People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccinationMurat Gainullin, Lorenzo Federico, Julie Røkke Osen, et al.
Nature Communications|July 19, 2022
Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adultsHassen Kared, Asia-Sophia Wolf, Amin Alirezaylavasani, et al.
Frontiers in Immunology|March 8, 2024
Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort studyHassen Kared, Ingrid Jyssum, Amin Alirezaylavasani, et al.
Frontiers in Immunology|July 28, 2023
Robust spike-specific CD4+ and CD8+ T cell responses in SARS-CoV-2 vaccinated hematopoietic cell transplantation recipients: a prospective, cohort studyLorenzo Federico, Tor Henrik Anderson Tvedt, Murat Gainullin, et al.
Biorxiv : the Preprint Server for Biology|October 14, 2020
CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome and show kinetics of early differentiationHassen Kared, Andrew D Redd, Evan M Bloch, et al.
The Journal of Clinical Investigation|January 11, 2021
SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individualsHassen Kared, Andrew D Redd, Evan M Bloch, et al.
European Heart Journal|August 18, 2021
Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopeniaSverre Holm, Hassen Kared, Annika E Michelsen, et al.
Nature Communications|February 12, 2020
Immunological history governs human stem cell memory CD4 heterogeneity via the Wnt signaling pathwayHassen Kared, Shu Wen Tan, Mai Chan Lau, et al.
International Journal of Biological Macromolecules|February 8, 2024
PeptiVAX: A new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccinesSara Feola, Jacopo Chiaro, Manlio Fusciello, et al.
Pageof 5